About
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.
Company Website : http://www.bavarian-nordic.com
Address : Philip Heymans Alle 3, Hellerup, Denmark, 2900
Employees : 649
Fiscal Year End : December
Currency:
USD
Country :
USA